All In Biotech

Drug Trial Radar · NCT06684314

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan

PROphylactic Efanesoctocog Alfa Therapy Evaluated for Critical Joint Health in Hemophilia A Treatment: The PROTECT-ALT Study

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

79

Actual

Start

Nov 11, 2024

Primary completion

Aug 28, 2031

Study completion Aug 28, 2031

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a national, multicenter, retrospective/prospective, observational study in Taiwan designed to assess effectiveness, safety, and usage of efanesoctocog alfa prophylaxis treatment in hemophilia A participants. The data related to efanesoctocog alfa effectiveness, safety and usage will be recorded prospectively during routine visits for up to 5 years following enrollment initiation and the retrospective data will be collected at least 12 months and up to 24 months prior to efanesoctocog alfa initiation. Joint imaging data will be collected in centers performing Joint U/S and/or MRI (≥6 years old). At least 12 months of retrospective data will also be collected from medical records, as available. Prospectively collected data will be recorded at routine clinical visits during a five-year follow-up period. The end of study is defined as the last participant's last visit. No intervention will be administered, and no study related visits are required.

Conditions

  • Hemophilia A

Interventions

  • Efanesoctocog alfaDrug

    This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in total scores of the Hemophilia Joint Health Score (HJHS) for all jointsTime frame: At 1, 2, 3, 4 and 5 years
  2. Change from baseline in annualized joint bleeding rate (AjBR) for treated and untreated bleedsTime frame: At 1, 2, 3, 4 and 5 years
  3. Number of target joint development, resolution and/or recurrenceTime frame: At 1, 2 ,3, 4 and 5 years

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 1580008

    Changhua, Taiwan

  • Investigational Site Number : 1580009

    Kaohsiung City, Taiwan

  • Investigational Site Number : 1580010

    Kaohsiung City, Taiwan

  • Investigational Site Number : 1580003

    New Taipei City, Taiwan

  • Investigational Site Number : 1580005

    Taichung, Taiwan

  • Investigational Site Number : 1580006

    Taichung, Taiwan

  • Investigational Site Number : 1580007

    Taichung, Taiwan

  • Investigational Site Number : 1580001

    Taipei, Taiwan

  • Investigational Site Number : 1580002

    Taipei, Taiwan

  • Investigational Site Number : 1580004

    Taoyuan City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.